养血清脑颗粒联合阿立哌唑治疗精神分裂症的临床研究

目的探讨养血清脑颗粒联合阿立哌唑治疗精神分裂症的临床疗效。方法选择2016年1月—2018年5月武汉市优抚医院收治的精神分裂症患者94例,随机分为对照组(47例)和治疗组(47例)。对照组患者口服阿立哌唑片,第一周剂量为5 mg/d,第二周剂量为10 mg/d,然后依据患者的耐受情况增加剂量至15 mg/d,1次/d。治疗组患者在对照组的基础上口服养血清脑颗粒,4g/次,3次/d。两组患者均连续治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者阳性和阴性症状评定量表(PANSS)评分、社会认知功能评分及血清白细胞介素-2(IL-2)、IL-6、神经生长因子(NGF)及和脑源性神经营养因子(BDNF)水平。结果治疗后,对照组临床有效率为76.60%,显著低于治疗组的93.62%,两组比较差异具有统计学意义(P0.05)。治疗后,两组PANSS和社会认知功能评分均明显小于治疗前(P0.05),且治疗组患者这些评分明显低于对照组(P0.05)。治疗后,两组血清IL-2、IL-6、NGF及BDNF水平均明显低于治疗前(P0.05),且治疗组血清IL-2、IL-6、NGF及BDNF水平明显低于对照组(P0.05)。结论养血清脑颗粒联合阿立哌唑治疗精神分裂症的临床疗效显著,能够明显改善临床症状和社会认知功能,且安全性较好,具有一定的临床推广应用价值。

Clinical study on Yangxue Qingnao Granules combined with aripiratole in treatment of schizophrenia

Objective To explore the clinical efficacy of Yangxue Qingnao Granules combined with aripiratole in treatment of schizophrenia. Methods Patients (94 cases) with schizophrenia in Wuhan Excellent Hospital from Januaryr 2016 to May 2018 were randomly divided into control (47 cases) and treatment (47 cases) groups. Patients in the control group were po administered with Aripiprazole Tablets, 5 mg/time for the first week, 10 mg/time for the first week, then the dose was increased to 15 mg/d, once daily. Patients in the treatment group were po administered with Yangxue Qingnao Granules on the basis of the control group, 4 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the PANSS scores, the social cognitive function scores, the serum IL-2, IL-6, NGF, BDNF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 76.60%, which was significantly lower than 93.62% in the treatment group, and there were differences between two groups (P<0.05). After treatment, PANSS and the social cognitive function scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum IL-2, IL-6, NGF, BDNF levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). Conclusion Yangxue Qingnao Granules combined with aripiratole has a good efficacy and low adverse reactions in treatment of schizophrenia, can significantly improve the clinical symptoms and social cognitive function, which has a certain clinical application value.